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The transient receptor potential melastatin-related channel 2
(TRPM2) is a nonselective cation channel, whose prolonged activa-
tion by oxidative and nitrative agents leads to cell death. Here, we
show that the drug puromycin selectively targets TRPM2-express-
ing cells, leading to cell death.Our data suggest that the silent infor-
mation regulator 2 (Sir2 or sirtuin) family of enzymes mediates this
susceptibility to cell death. Sirtuins are protein deacetylases that
regulate gene expression, apoptosis, metabolism, and aging. These
NAD-dependent enzymes catalyze a reaction in which the acetyl
group from substrate is transferred to the ADP-ribose portion of
NAD to form deacetylated product, nicotinamide, and the metab-
olite OAADPr, whose functions remain elusive. Using cell-based
assays and RNA interference, we show that puromycin-induced cell
death is greatly diminished by nicotinamide (a potent sirtuin inhib-
itor), and by decreased expression of sirtuins SIRT2 and SIRT3.
Furthermore, we demonstrate using channel current recordings
and binding assays that OAADPr directly binds to the cytoplasmic
domain of TRPM2 and activates the TRPM2 channel. ADP-ribose
binds TRPM2 with similarly affinity, whereas NAD displays
almost negligible binding. These studies provide the first evidence
for the potential role of sirtuin-generated OAADPr in TRPM2
channel gating.
Transient receptor potential melastatin-related channel 2 (TRPM2)4
is a non-selective cation channel mainly expressed in brain, gastrointes-
tinal tissues, and certain immune cells (reviewed in Ref. 1). Although the
physiological function of TRPM2 remains unclear, several reports have
demonstrated that TRPM2 expression confers susceptibility to cell
death in response to oxidative (H2O2) and nitrative stress (2, 3). Under
these conditions, TRPM2 appears to induce cell death by causing an
overwhelming influx of Na2 and Ca2 (2). This influx is thought to
occur as a consequence of TRPM2 channel activation via ADP-ribose
(ADPr) binding to the cytoplasmic, C-terminal domain of the channel.
This domain, termedNudT9-H (NudT9 homology), contains an appar-
entNudix enzymaticmotif and shares significant homology to themito-
chondrialNudT9 enzyme (4, 5), amember of theNudixADPr hydrolase
family. Indeed, electrophysiology experiments have shown that low
micromolar levels of ADPr activate the TRPM2 channel (4, 6), and that
this activation is mediated through the NudT9-H domain (7, 8), impli-
cating a direct ADPr and NudT9-H interaction.
The NudT9-H domain has been reported to have hydrolytic activity
toward ADPr, albeit at a 100-fold lower rate than NudT9 (4, 9).
Although it was initially thought that the ADPr hydrolase activity of
TRPM2might have a role in regulating TRPM2 gating via hydrolysis of
bound ADPr, recent data have demonstrated that mutations in putative
catalytic residues of NudT9-H do not affect TRPM2 channel gating,
leaving the function of this activity unclear (8). Some studies suggest
that hydrogen peroxide directly activates the TRPM2 channel (3, 10);
however, it has been reported recently that this oxidative agent acts
indirectly by triggering the release of ADPr from an intracellular com-
partment (8, 11). The mechanism of TRPM2 activation by hydrogen
peroxide may prove to be more complex, as hydrogen peroxide and
ADPr have also been suggested to act cooperatively in TRPM2 channel
activation (12).
In this article, we have investigated the ability of TRPM2 to sensitize
cells to cellular insults other than those inducing oxidative stress. Here,
we demonstrate that puromycin, a well known pleiotropic cell stress
agent, selectively targets TRPM2-expressing cells, leading to cell death.
Our studies suggest that Sir2 enzymes play an important role in medi-
ating this response. We found that TRPM2 has the capacity to sense
OAADPr, the unique metabolite of the Sir2 protein deacetylase reac-
tion, and induce cell death in response to puromycin. Furthermore, we
report the first direct evidence that OAADPr binds to the NudT9-H
domain and modulates TRPM2 channel activity. Our data have impor-
tant implications for the potential physiological roles of ADPr-related
molecules as secondarymessengers. This report links Sir2 enzymes (sir-
tuins) with the TRPM2 channel through the Sir2 metabolite OAADPr.
This newly discovered association provides a plausible mechanism for
previously described sirtuin functions, which include control of stress
response pathways and metabolic regulation.
EXPERIMENTAL PROCEDURES
Cell Culture—HEK-293 and tetracycline (tet)-inducible HEK-293
TRPM2-expressing cells (4) were cultured in DMEM and 10% fetal
bovine serum at 37 °C, 5% CO2. Medium used to culture tet-inducible
HEK-293 cells was supplemented with blasticidin (5 g/ml; Invitrogen)
and zeocin (0.4 mg/ml; Invitrogen). To induce expression of TRPM2 in
recombinant HEK-293 cells, tet was added to the medium at 1 g ml1
(Invitrogen) 24 h prior to experiments. The CRI-G1 rat -islet tumor
cell line was obtained from EACC and cultured in DMEM, 10% fetal
bovine serum, and 2 mM glutamine.
Cell Viability Assays—HEK-293, tet-inducible HEK-293, and CRI-
G1 cells were seeded into 6-well plates at a density of 500,000 cells per
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well.When cells were 50–70% confluent, puromycin (Sigma)was added
to the medium at various concentrations, and the cells were incubated
for 16 h (unless otherwise indicated). Cell monolayers were rinsed with
PBS, after which 0.5 ml of 2 M calcein (Molecular Probes) in PBS was
added directly to the well for 10–20 min. Calcein is retained in living,
but not dead cells, where it undergoes catalytic conversion into a fluo-
rescent compound. Fluorescence in each well wasmeasured in amicro-
plate reader using excitation and emission filters at 485/530 nm,
respectively.
Calcium Depletion—When TRPM2-expressing HEK-293 cells were
80–90% confluent, they were rinsed with PBS, and incubated in DMEM
lacking calcium chloride in the presence of 5mMEGTAand 1g/ml tet.
One hour after calcium removal, cells were treated with 0, 50, 100, 200,
or 500 M puromycin for 6 h. At this time cells remained adherent and
were assayed for viability as described above.
Detection of FLAG-TRPM2 by Western Blot Analysis—HEK-293
TRPM2-expressing cells were grown in the presence or absence of tet (1
g/ml) for 24 h. Cells were then rinsed with PBS and lysed directly on
the plate with 1 protein sample buffer. Whole cell extracts were re-
solved on a 6% SDS-PAGE gel, and transferred onto a polyvinylidene
difluoride membrane. Expression of FLAG-TRPM2 was detected by
standard Western blot procedure using a M2 monoclonal anti-FLAG
antibody (Sigma).
Knockdown of SIRT2 and SIRT3 Transcription using siRNA—Tet-
inducibleHEK-293 cells were transfectedwith 100 nM control, SIRT2 or
SIRT3 siRNA (Dharmacon) using Trans-IT TKO transfection reagent
(Mirus). After 24 h, TRPM2 expressionwas induced by addition of tet to
the medium. 48-h post-transfection, one set of cells was harvested and
analyzed for SIRT expression as described below, and the rest were
treated with puromycin for an additional 16 h and assayed for viability.
Analysis of SIRT2 and SIRT3 Transcripts by RT-PCR—Total RNA
was isolated from harvested cells using TRIzol reagent (Invitrogen).
RNA was reverse-transcribed using random hexamers and AMV-RT
(Promega). The RT reaction was used as a template for PCR amplifica-
tion of SIRT2 or SIRT3 using primer pairs: 5-CAGAACATAGATAC-
CCTGGAGCGAA and 5-AAGGTCCTCCAGCTCCTTCTTC and
5-TGAGAGAGTGTCGGGCATCCCTG and 5-TCATCCTATTT-
GTCTGGTCCATCAA, respectively. Primers 5-GGCACCACACCT-
TATACAAT and 5-ATGTCACGCACGATTTCCwere used to amplify
actin, which served as an internal PCR control.
Detection of SIRT2 and SIRT3 Protein by Western Blot Analysis—Cells
were lysed in 50mMTris-HCl, pH 8.0, 150mM sodium chloride, 1% Igepal
CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM
phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, and 10 g/ml leupep-
tin. Cytosolic and mitochondrial fractions were separated using a mito-
chondrial isolation kit (Pierce) according to the manufacturer’s instruc-
tions. SIRT2 and SIRT3 protein were detected by standard Western blot
protocol using chicken anti-SIRT2 antibody (13) and rabbit anti SIRT3
antisera (14), respectively (antibodies were graciously provided by Dr. Eric
Verdin, UCSF).
Synthesis and Purification of OAADPr—As previously described
(15–18),OAADPr was generated in a reaction including 50mMTris-Cl,
pH 7.5, 1.8 mM acetylated histone peptide, 800 M NAD, and 40 M
Hst2 (yeast Sir2 homolog). After 60 min at 37 °C, NADase (Sigma) was
added to degrade the remaining NAD. The reaction was quenched 15
min after NADase addition with trifluoroacetic acid (1% final), and
OAADPr was separated from other components in the reaction by C18
reverse-phase chromatography (Grace Vydac). Based on HPLC analysis,
OAADPr was determined to be95% pure.
Channel Gating—Patch clamp electrophysiology was performed as
previously described (4). Briefly, cells were patch clamped in the whole
cell configuration at 25 °C using pipettes with resistances ranging from
2–3 MOhms. Currents were recorded on an EPC9 patch clamp ampli-
fier with automatic capacitance compensation using a protocol gener-
ating a 50ms voltage ramp from100 to100mv every 2 s at a holding
potential of 0mv (appropriately corrected for liquid junction potential).
Bath solution included 150 mM NaCl, 2.8 mM KCl, 5 mM CsCl, 1 mM
CaCl2, 2mMMgCl2, and 10mMHepes, pH7.2. Pipette solution included
135 mM cesium glutamate, 1 mMMgCl2, 8 mMNaCl, 10 mMHepes, pH
7.2, and either no EGTA (unbuffered conditions) or 10mMEGTA (buff-
ered conditions) as indicated. For low resolution presentation of current
development over the course of the experiment, instantaneous currents
at80 mv were extracted from each ramp and plotted versus time.
Cloning, Expression, and Purification of the NudT9-H Domain—The
DNA sequence encoding residues 1195–1503 of human TRPM2 (long
isoform) was amplified by PCR using primers: 5-AAGCATGCGT-
GAGGACGCTG and 5-ACAAGCTTTCAGTAGTGAGC. The prim-
ers introduced an upstream SphI and a downstream HindIII recog-
nition site (underlined) at the termini of the amplified DNA. The
PCR product was gel-purified, digested with SphI and HindIII, and
cloned into pQE80 (Qiagen) downstream and in-frame with sequence
encoding a His6 tag. The cloned plasmid was then sequenced to ensure
no mutations were present. The plasmid was introduced into the
BL21(DE3)pLys strain of Escherichia coli, and the NudT9-H protein
induced by adding isopropyl-1-thio--D-galactopyranoside (0.4 mM
final) to the culture once A600 reached 0.5. After a 5 h induction at
30 °C, the bacteria were harvested, resuspended in buffer A: 50 mM
Tris-Cl, pH 7.6, 300 mM NaCl, 1 mM -mercaptoethanol, 10 g/ml
leupeptin, 1mMphenylmethylsulfonyl fluoride, and lysed by sonication.
The NudT9-H protein was purified by affinity chromatography using
nickel-Sepharose resin, followed by cation exchange. The final protein
preparation was dialyzed in 50 mM Tris-Cl 7.6, pH 7.6, 0.5 mM TCEP,
and stored at 80 °C. Protein concentration was determined by Brad-
ford assay (Bio-Rad) using bovine serum albumin as standard.
Isothermal Calorimetry (ITC)—Binding assays were performed on
a VP-ITC instrument (MicroCal) at 25 °C. ADPr, AMP, and NAD
(Sigma) were resuspended in the same buffer used to store the NudT9-H
protein: 50 mM Tris-Cl pH 7.6, 0.5 mM TCEP, and the ligand concen-
trationwas determined spectrophotometrically. NudT9-Hprotein con-
centration was 30–35 M, whereas ligand concentrations in the injec-
tion syringe were 2–4 mM. The data were fitted using the Origin
software (Originlab), assuming a 1:1 stoichiometry of binding.
Synthesis and Purification of [32P]-N3-OAADPr—[32P]-N3-OAADPr
was generated through two enzymatic steps. First, [32P]-N3-ATP (Affin-
ity Labeling Technologies) and NMN (nicotinamide mononucleotide)
weremixed in a 1:3molar ratio, together withNMNAT (NMNadenylyl
transferase). After 1 h at 37 °C, the reaction was quenched in 1% triflu-
oroacetic acid. [32P]-N3-NAD, the product of the reaction, was puri-
fied by C18 reverse phase chromatography. [32P]-N3-OAADPr was syn-
thesized the same way as described under “Synthesis and Purification of
OAADPr” except that [32P]-N3-NAD was used instead of NAD.
NAMAT was expressed from a plasmid generously provided by Dr.
Mathias Ziegler (Freie Universitat Berlin).
[32P]-N3-OAADPr photocross-linking—NudT9-H (2 M) was incu-
bated in a 300-l reaction containing 20 mM Tris-Cl (pH 7.25), 1 mM
MgCl2, [32P]-N3-OAADPr (6.5 M, 1  106 cpm), and varying con-
centrations of cold (unlabeled) OAADPr, ADPr, or NAD. Reactions
were incubated at 4 °C for 20min. In separate control reactions, 2M of
bovine serum albumin or heat-denaturedNudT9-H (5min, 95 °C) were
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used instead. Samples were then photolyzed for 8min using a hand held
UV lamp (Mineralight Model UVG-11). Any remaining reactive azido
groupswere quenchedwith 10mMdithiothreitol. Samples were trichlo-
roacetic acid-precipitated, resolved by SDS-PAGE, and visualized by
phosphorimaging.
RESULTS
Expression of TRPM2 confers susceptibility to cell death in response
to a variety of oxidative and nitrative agents, particularly hydrogen per-
oxide (2, 3). Given the sensitivity of TRPM2-expressing cells to oxida-
tive stress, we questioned whether other types of chemical affronts
could lead to TRPM2 channel activation, and subsequent cell death.We
focused our attention on pleiotropic drugs: cycloheximide and puromy-
cin, both of which inhibit protein translation and can lead to apoptosis.
We performed a series of cell survival studies following cycloheximide
or puromycin treatment of stably transfectedHEK-293 cells harboring a
tet-inducible TRPM2 gene. As displayed in Fig. 1a, cells expressing
TRPM2 did not exhibit increased sensitivity to cycloheximide com-
pared with control cells (non-induced and parental HEK 293 cells). In
contrast, tet-induced TRPM2-expressing cells displayed a profound
sensitivity to puromycin-dependent cell death with as little as 5 M
puromycin (Fig. 1b). The dose response curve, displayed a strong
dependence up to 50 M puromycin. In the absence of TRPM2 expres-
sion (Fig. 1c), cells exhibited nearly complete protection against puro-
mycin-dependent cell death (Fig. 1b). Parental HEK-293 cells showed
no significant cell death following puromycin treatment (5–50 M) in
the absence (Fig. 1b) or presence of tet (data not shown). These data
indicate that TRPM2 expression renders cellsmore susceptible to puro-
mycin, but not cycloheximide, mediated cell death, and suggest that
inhibition of protein synthesis alone is insufficient to cause cell death via
activation of the TRPM2 channel.
Full activation of the TRPM2 channel is dependent on extracellular
Ca2 (2, 19–21), thus, we examined whether puromycin-induced cell
death in TRPM2-expressing cells required the presence of extracellular
Ca2. Because prolonged incubation inCa2-freemedium in itself leads
to cell death over time, we assayed cell viability in Ca2-free medium at
6 h rather than 16-h post-drug treatment, and adjusted the range of
puromycin concentration accordingly to 100–600 M. The removal of
Ca2 1 h prior to drug treatment completely blocked puromycin-in-
duced cell death in TRPM2-expressing cells (Fig. 1d). These results dem-
FIGURE 1. a, TRPM2 expression in HEK-293 cells does not lead to preferential sensitivity to cycloheximide. HEK-293 (closed diamond) and TRPM2-expressing HEK-293 cells in the
absence (open diamond) or presence of (closed square) tet were exposed to 0–10 g/ml cycloheximide for 16 h. Cell viability was assayed by measuring calcein fluorescence in live,
adherent cells. b, puromycin leads to cell death in TRPM2-expressing HEK-293 cells. Shown are parental HEK-293 cells (closed diamond) and tet-inducible TRPM2-expressing HEK-293
cells in the presence (open squares) or absence of (open diamonds) tet. Cells incubated in the presence of 0–50M puromycin for 16 h were assayed for viability as described above.
c, FLAG-TRPM2 protein is detected in tet-induced () but not non-induced () HEK-293 TRPM2 cells. d, removal of calcium rescues cells from puromycin-induced cell death.
TRPM2-expressing HEK-293 cells were grown in DMEM/10% fetal bovine serum and 1 g/ml tetracycline until 80–90% confluent. One set of cells was fed with DMEM (closed
diamonds), and theother setwas fedwithDMEM lacking calciumchloride (open squares) in thepresenceof 5mMEGTA.Onehour after calcium removal, cellswere incubated in 0–500
M puromycin for 6 h after which cell viability was measured as described above.
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onstrate that the observed puromycin-induced cell death is dependent on
Ca2 and, provides additional support for puromycin activation of the
TRPM2 channel.
The above results suggest that puromycin causes sustained TRPM2
channel activation in HEK-293 cells, by means other than protein syn-
thesis inhibition, leading to cell death.We hypothesized that themolec-
ular link between puromycin and TRPM2 channel gating may be acti-
vation of poly(ADP-ribose) polymerase 1 (PARP-1). As a precursor to
apoptosis, PARP-1 is activated in response to cellular signals and DNA
damage (reviewed in Ref. 22). This nuclear enzyme synthesizes poly-
(ADP-ribose) from NAD and attaches the polyADP-ribosyl moiety
onto multiple protein targets. Poly(ADP-ribose) can be rapidly hydro-
lyzed by PARG (poly(ADP-ribose) glycohydrolase) to formADP-ribose,
which could then activate the TRPM2 channel. We investigated whether
PARP inhibitors 3-aminobenzamide and nicotinamide could protect
TRPM2-expressing cells from puromycin-induced cell death. Curiously,
3-aminobenzamide, a potent PARP inhibitor displaying an IC50 of 5
M in vivo (23), had no effect on puromycin-induced cell death even at
1.5 mM (Fig. 2a). In contrast, nicotinamide (500 M) completely pro-
tected puromycin-induced cell death up to concentrations as high as 20
M puromycin (Fig. 2b). Only at a much higher puromycin concentra-
tion (50 M) could the protection afforded by nicotinamide be sup-
pressed. In vivo, nicotinamide inhibits PARP-1 at an IC50 of 100M (23),
and is therefore a considerably weaker PARP-1 inhibitor than 3-amino-
benzamide. These results suggested that nicotinamide protection from
puromycin-induced cell death occurs through a mechanism distinct
from PARP inhibition.
We hypothesized that nicotinamide could be inhibiting a different
class of NAD-dependent enzymes, in particular, the Sir2 family of
histone/protein deacetylases. Members of this family have been shown
to regulate numerous cellular functions including: gene expression,
apoptosis, metabolism, differentiation, and aging (reviewed in Ref. 24).
Seven homologues of the prototypic yeast Sir2 enzyme have been iden-
tified inmammalian cells (SIRT1–7) (25, 26), and nicotinamide, a prod-
uct of the Sir2 deacetylation reaction, is a potent inhibitor of Sir2
enzymes, displaying IC50 values in the low micromolar range (27–29).
We examined whether two likely candidates, cytoplasmic SIRT2 and
mitochondrial SIRT3, could mediate the puromycin-induced TRPM2
channel gating. RNA interference (siRNA) was used to knockdown the
endogenousmRNA and protein levels, and the resulting effect on puro-
mycin-induced cell death was assessed (Fig. 3). In these experiments, a
nonspecific siRNA control and siRNA specific for SIRT2 and SIRT3
were used. As shown in Fig. 3a, each siRNA demonstrated strict speci-
ficity, only knocking down its corresponding RNA and protein, whereas
having no effect on the other. After siRNA treatment, endogenous levels
of SIRT3 protein in whole cell extracts could no longer be detected.
Similar knockdownwas seen with SIRT2 siRNA treatment. Data shown
in Fig. 3b represent averages obtained from five separate experiments
(including standard deviations) with five different concentrations of
puromycin. Relative to nonspecific siRNA transfection, cells transfected
with either SIRT2 or SIRT3 siRNAs displayed significant resistance to
puromycin-induced cell death in TRPM2-expressing HEK-293 cells
(Fig. 3b). At 20 M puromycin, loss of SIRT2 or SIRT3 increased
cell survival 2–3-fold, and by 50 M puromycin, 30% of the origi-
nal cell number was still viable, whereas survival of control siRNA-
treated cells was negligible.
The above results showed that depletion of SIRT2 or SIRT3 confers
protection from puromycin death in TRPM2-expressing cells. Because
these two enzymes reside in different cellular regions, it is unlikely that
they deacetylate the same substrates. However, both enzymes catalyze
an NAD-dependent reaction in which the acetyl group is transferred
to the ADP-ribose portion of NAD to generate the metabolite
OAADPr (15, 17, 30, 31). We postulated that OAADPr, the product of
the Sir2 reaction, might accumulate during puromycin treatment and
cause TRPM2 channel activation. Given the structural similarity of
OAADPr to ADPr, we hypothesized that OAADPr may be responsible
for directly gating the TRPM2 channel. To test this hypothesis, we per-
formed whole cell patch clamp experiments in TRPM2-expressing
HEK-293 cells.We found that inclusion ofOAADPr in the patch pipette
solution induced currents in TRPM2-expressing cells, (Fig. 4b), but not
whenTRPM2was absent (Fig. 4c).OAADPr activated thesewith similar
kinetics and dose dependence to that of ADPr (compare Fig. 4, a and b,
top panels). These currents were characteristic of TRPM2 as they were
absent when TRPM2 expression was absent (Fig. 4c), exhibited a linear
I/V relationship characteristic to TRPM2 (Fig. 4, a and b, bottom pan-
FIGURE 2. a, PARP inhibitor 3-amino-benzamide does not block puromycin-induced cell
death. TRPM2-expressing HEK-293 cells were exposed to 0–50M puromycin for 16 h in
thepresence (opendiamond) or absence (closed diamond) of 1.5mM3-aminobenzamide.
Cell survival was determined bymeasuring fluorescence of calcein in live, adherent cells.
Results (with standarddeviations) are representative of twoormore independent exper-
iments. b, nicotinamide blocks puromycin-induced cell death in TRPM2-expressing cells.
TRPM2-expressing HEK-293 cells were exposed to 0–50 M puromycin for 16 h in the
presence (open diamond) or absence (closed diamond) of 500 M nicotinamide. Cell via-
bility was then measured as described above.
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els), and were potentiated when intracellular Ca2 was left unbuffered
(Fig. 4d). After performing the above experiments, we determined that
spontaneous breakdown of OAADPr to ADPr in the patch pipette was
5–10%. As this level of breakdownwould not allow for sufficient accu-
mulation of ADPr to induced channel gating, these data are consistent
with OAADPr, and not the breakdown product ADPr, acting as the
direct ligand in the recordings. The similarity of the dose response rela-
tionship for OAADPr-mediated gating of TRPM2 to that for ADPr-
mediated gating of TRPM2 further suggests thatOAADPr activates the
TRPM2 channel as effectively as ADPr, andmay indeed serve as a phys-
iological regulator of TRPM2.
To verify that puromycin does not directly gate the TRPM2 channel,
whole cell channel recordings were performed with 100 M puromycin
alone, which showed no affect on channel activity (data not shown).
Also, there was no significant enhancement ofOAADPr-gated TRPM2
channel activity in whole cell recordings when 125–250 M puromycin
was included in the patch pipette (Fig. 4e). These data demonstrate that
puromycin does not directly gate the TRPM2 channel, nor does it mod-
ulate TRPM2 gating properties in response to OAADPr. Therefore,
puromycin is indirectly responsible for TRPM2-dependent cell death,
possibly by mediating OAADPr accumulation. The mechanism by
which puromycin leads to increased levels ofOAADPr is unclear; how-
ever puromycinmight increase sirtuin activity or inhibit the breakdown
pathways of OAADPr.
We sought to substantiate our observations of OAADPr-gated
TRPM2 activity using a genetically unmodified cell line. TRPM2 is
highly expressed in rat microglia (32), and has been described in gran-
ulocytes (4, 6, 33), rat insulinoma cell lines (2, 20, 34), and pancreatic
-islets (35). We chose to conduct experiments on CRI-G1 (rat -islet
insulinoma) cells, in which the endogenous TRPM2 channel has been
well characterized (11, 20, 34, 36–38). Puromycin treatment of CRI-G1
cells led to dose-dependent cell death at the same range of puromycin
concentrations as those used in the TRPM2-inducible HEK-293 system
(Fig. 5a). In addition, the Sir2 inhibitor nicotinamide was able to protect
cells from puromycin-induced death in a dose-dependent manner (Fig.
5a, inset), whereas the PARP inhibitor 3-aminobenzamide showed no
protective effect (data not shown).Most importantly,OAADPrwas able
to directly mediate gating of currents in CRI-G1 cells, which exhibited
the characteristic TRPM2 I/V relationship (Fig. 5b, bottom panel).
Inclusion of OAADPr in the patch pipette produced evolution of aver-
age currents of 2 nA with a highly linear I/V relationship characteristic
of TRPM2. No current evolution was detected in the absence of
OAADPr (light gray curve, Fig. 5b), whereas the evolution of the
OAADPr-induced currents occurred over a time course consistent with
diffusional equilibration ofOAADPr into the cell from the patch pipette.
Overall, these results support the physiologic relevance of OAADPr in
regulating TRPM2 channel gating.
We next asked whether OAADPr activates the channel via direct
binding to the NudT9-H domain. This domain may regulate TRPM2
channel gating by differentially binding to small, adenosine-containing
ligands, such as NAD, ADPr,OAADPr, and AMP. However, no report
had demonstrated direct, biologically relevant binding to this domain.
To examine whether these molecules directly bind to NudT9-H, we
performed ITC binding experiments using recombinant purified
NudT9-H from TRPM2. Whereas no NAD binding was observed up
to the limit of detection (250 M), ADPr bound NudT9-H with a Kd of
130 M (Fig. 6a), in agreement with the observed EC50 for ADPrR-
mediated TRPM2 gating (4). AMP also bound NudT9-H, albeit at a
lower affinity than ADPr (Kd  166 M) (data not shown), consistent
with a recent report demonstrating that AMP inhibits ADPr-mediated
TRPM2 channel activation, displaying an IC50 of 70 M (12). Unfor-
tunately, because of high concentrations of ligand required for the ITC
experiments, we were unable to generate sufficient quantities of
OAADPr for ITC analysis. We, therefore, used a UV-cross-linking
approach to examine OAADPr binding to NudT9-H. We generated
[32P]-N3-OAADPr, a [32P]-labeled OAADPr compound with an UV
reactive azido (N3) group attached to the adenine ring. [32P]-N3-
OAADPr was incubated with NudT9-H in the absence or presence of
FIGURE3.a–c, detectionof SIRT2 andSIRT3mRNAandprotein levels in siRNA-treatedTRPM2-expressingHEK-293 cells. Cells treated for 48hwith100nMcontrol, SIRT2, or SIRT3 siRNA
were harvested and analyzed for knock-down in SIRT2 and SIRT3 expression. a, presence of SIRT2 and SIRT3 transcripts was detected by RT-PCR. The amount of total RNA used for
RT-PCRwas normalized to that of actin. b, endogenous SIRT2protein levelswere detectedbyWestern blot using anti-SIRT2 antibody. c, SIRT3 protein, detectedbyWestern blot using
anti-SIRT3 antisera, was detected in themitochondrial but not the cytosolic fraction. d, siRNA knock-down of endogenous SIRT2 and SIRT3 protein protects cells against puromycin-
induced death. TRPM2-expressing HEK-293 cells were transfectedwith 100 nM nonspecific control, SIRT2, or SIRT3 siRNA. After 48 h, cells were exposed to 0–50M puromycin for an
additional 16 h. Cell survival was determined bymeasuring fluorescence of calcein in live cells, and plotted as a fraction relative the no puromycin control. Results are averages (with
standard errors) from six separate experiments. **, indicates p 0.05 from analysis of variance statistical analysis, comparing siRNA control data with that of SIRT2 or SIRT3 at each
puromycin concentration.
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increasing concentrations of unlabeled OAADPr, ADPr, or NAD
competitor. As shown in Fig. 6b, [32P]-N3-OAADPr readily cross-linked
with NudT9-H. No radiolabel was incorporated when heat-denatured
NudT9-H or BSA were used in parallel controls experiments (data not
shown), indicating that [32P]-N3-OAADPr specifically binds to a struc-
tured component of the NudT9-H domain. Increasing amounts of
either cold OAADPr or ADPr efficiently competed away the [32P]-N3-
OAADPr from the binding site on NudT9-H, suggesting that ADPr and
OAADPr bind to the same pocket (Fig. 6b). Quantitation of the signal
intensities, plotted in Fig. 6c, shows that both OAADPr and ADPr bind
to NudT9-Hwith similar affinity (90–100MKd), in good agreement
with values from the ITC experiments. On the other hand, NAD did
not efficiently compete for binding, since a 100-fold molar excess of
NAD decreased the radiolabel signal intensity by 54% (data not
shown). This small decrease can be partially attributed to the amount of
contaminating ADPr (estimated to be3% by HPLC analysis), which is
typical of commercial NAD preparations. Taking this into account, we
estimate that NAD binds NudT9-H with a 20-fold lower affinity
than ADPr or OAADPr. These data provide the first evidence of direct
OAADPr, ADPr, and AMP binding to the NudT9-H domain, and pro-
vide new insight into the regulation of the TRPM2 channel.
DISCUSSION
In this study, we explored the ability of TRPM2 to sensitize cells to
metabolic perturbations other than those that induce oxidative stress.
Using cell viability assays, we found that the drug puromycin confers
high susceptibility to death in TRPM2-expressing cells, through a
mechanism distinct from inhibition of protein translation. We further
show that nicotinamide effectively protects cells from puromycin-in-
duced death, and that this protection is consistent with inhibition of the
Sir2 family of NAD-dependent protein deacetylases. Specifically,
siRNA experiments revealed that depletion of either cytoplasmic SIRT2
or mitochondrial SIRT3 protein results in protection from puromycin
death in TRPM2-expressing cells. A common feature of Sir2 enzymes is
the generation of OAADPr through an NAD-dependent protein
deacetylation reaction. We postulated that SIRT2 and SIRT3 might
contribute to the accumulation of cellularOAADPr, leading to TRPM2-
dependent cell death. Indeed, we found that OAADPr activates the
TRPM2 channel with similar kinetics and dose dependence to that of
ADPr, a postulated ligand of TRPM2. Most significantly, we demon-
strate using UV cross-linking experiments that OAADPr directly binds
theNudT9-Hdomain of the channel. These data are consistent with the
idea thatOAADPr produced by SIRT2 and SIRT3 is responsible for the
TRPM2 activation and provide compelling evidence that OAADPr is a
regulator of TRPM2.
No detectable binding of NAD to the NudT9-H domain (up to 250
M) was observed by ITC, whereas ADPr bound with a Kd of130 M.
UV-cross-linking experiments revealed that NAD weakly competes
with OAADPr for NudT9-H binding, with 20-fold lower efficiency
FIGURE 4.TheTRPM2channel is gatedbyOAADPr inHEK-293 cells. a–c, top panels illustrate the development ofwhole cell currents over time in TRPM2-expressingHEK-293 cells;
bottompanels show I/V relationships of currents shortly after break in, and at peak current development. Bath solutionwas standard Ringer’s, and pipette solutionwas Cs-based and
included 10 mM EGTA and the indicated concentrations of ADPR or OAADPr. a, HEK cells induced to express TRPM2 with ADPr-containing pipette solutions; b, HEK cells induced to
express TRPM2 with OAADPr-containing pipette solutions; c, non-induced HEK cells with 250 M OAADPr containing pipette solution. d, development of whole cell currents in HEK
cells induced to express TRPM2 with OAADPr-containing pipette solutions lacking EGTA. e, development of whole cell currents in HEK cells induced to express TRPM2 with pipette
solutions containing OAADPr (125 M) and puromycin as indicated.
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than ADPr. These data support the view that TRPM2 activation by
direct NAD interaction is unlikely, but rather, occurs after NAD
breakdown. The NudT9-H domain of the channel was reported to have
some hydrolytic activity toward ADPr (4, 9). However, recent data dem-
onstrated that mutations in putative catalytic residues of NudT9-H do not
affect channel gating (8). In our purified preparations of the NudT9-H
domain, we detected no NudT9-H enzyme activity under our sensitive
assay conditions (data not shown) (16), even though direct binding of
several ligands to NudT9-H was observed, precluding the possibility of
misfolded protein. These results provide strong additional evidence that
any intrinsic activity of the TRPM2 NudT9-H is not likely to be a sig-
nificant regulator of channel function. Intriguingly, we found that AMP,
FIGURE 5. a, puromycin leads to cell death in CRI-G1 cells. CRI-G1 cells were treated with 0–40M puromycin for 16 h. Cell viability was measured by detecting calcein fluorescence
in live, adherent cells. Data obtained from four independent experimentswereplotted as apercent change in fluorescence comparedwith thoseof untreated cells set at a 100%. Error
bars indicate the standard deviation from themean. Inset, nicotinamide rescues puromycin-induced death in CRI-G1 cells. CRI-G1monolayers were treated with 0, 0.5, 2, 4, 10, or 20
mMnicotinamide.After 30min, puromycinwasadded to themediumat a final concentrationof 20M.Cell viabilitywas assessed16h later asdescribedabove.Data are representative
of two independent experiments performed in duplicate. b, OAADPr gates the endogenous TRPM2 channel in CRI-G1 cells. Top panel, evolution of currents in CRI-G1 cells in the
absence (gray squares) or presence (black circles) ofOAADPr (120–250M). Shown are average leak-subtracted currents from n 3 cells for each condition. Bottom panel, represent-
ative leak subtracted whole cell I/V curves for peak currents observed in the absence (gray line) and presence (black line) ofOAADPr. For the abovemeasurements, CRI-G1 cells were
maintained in the whole cell patch clamp configuration as previously described for HEK-293 cells (4).
FIGURE 6. a, NudT9-H domain binds ADPr. Top panel, shown is the isothermal titration calorimetry profile for ADPr binding toNudT9-H. The first, small injectionwas not used for data
fitting. The subsequent nineteen data points were obtainedwith 4-l injections of 2mM ligand, followed by twenty 10-l injections. Bottom panel, data were fitted to an equilibrium
binding isotherm. The stoichiometry of binding (N) was set to 1. The Kd for the binding of ADPr to NudT9-H was determined to be 130	 3 M. b and c, the NudT9-H domain binds
OAADPrwith similar affinity as ADPr. Bindingwas performed using 2MNudT9-H, 6.5M [32P]-N3-OAADPr, and 0, 5, 10, 20, 40, or 100molar excess coldOAADPr or ADPr competitor.
Reactionswere incubated for 20minat 4 °Cprior toUVcross-linking. Resultswereobtainedbyphosphorimaging (b), and the signal intensitywasquantitatedandplottedas themolar
excess of cold competitor versus percent [32P]-N3-OAADPr bound (c).
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an antagonist of the TRPM2 channel (12), exhibited significant capacity
to bindNudT9-H (Kd 166M). Interestingly, the ratio ofAMP toATP
is a well known gauge of cellular energy status (Ref. 39 and references
therein). The possibility that the ratio of AMP/(ADPrOAADPr) may
play an analogous role in TRPM2 function is an intriguing idea to pos-
tulate. Sirtuin function is often associated with improved cellular health
and better utilization of available energy (40, 41). Under such condi-
tions, increased sirtuin activity and thus accumulation ofOAADPrmay
decrease the AMP/OAADPr and stimulate TRPM2 activity.
Studies have linked Sir2 enzymes to diverse functions, in particular,
the regulation of cell survival under stress (42–47). Human SIRT1, the
best studied yeast Sir2 orthologue, localizes to the nucleus where it
deacetylases a number of key proteins, including p53 (47–49), and Foxo
transcription factors (42, 44, 50, 51). Tissue-specific functions of SIRT1
include skeletal muscle differentiation (52), fat mobilization in adipo-
cytes (53), gluconeogenesis in the liver during fasting (54), and
enhanced glucose-stimulated insulin secretion (55). Less is known
about other human Sir2 members. SIRT2 is associated with microtu-
bules in the cytoplasm and can deacetylate -tubulin (13). The mito-
chondrial SIRT3 enzyme has been linked to longevity (56, 57), and the
regulation of thermogenesis in brown adipocytes (58).
There have been few reports investigating the biological func-
tion(s) of OAADPr and its possible connection with the observed
Sir2-dependent biology. It has been suggested that OAADPr might
be a substrate for other linked enzymatic processes, an allosteric reg-
ulator, or a second messenger. The first report of bioactivity came from
the observation that OAADPr injected into starfish oocytes or blas-
tomeres caused a block/delay in maturation and cell division, respec-
tively (18). Other roles, such as gene silencing, have been recently
ascribed to OAADPr based on in vitro experiments showing OAADPr
binding to macroH2A1.1, a histone variant found in heterochromatic
regions (59), and to the Sir2/3/4 silencing complex in yeast (60).
Enzymes capable of metabolizing OAADPr have been detected in sev-
eral diverse cells (16). In vitro, select members of the Nudix family of
ADPr hydrolases (e.g.mNudT5 and yeast YSA1) are capable of efficient
hydrolysis of OAADPr, whereas others like human Nudt9 are not (16).
In this study we have provided the first evidence that ADPr and
OAADPr bind the NudT9-H portion of the channel. It is likely that
both ADPr and OAADPr are physiologically important regulators of
TRPM2, but that they are generated from diverse cellular stimuli
and/or different pathways. For example, OAADPr may accumulate in
response to puromycin cell stress, whereas ADPr might accumulate
after hydrogen peroxide treatment, as previously suggested (8, 11).
Analogous to a recent report implicating mitochondria as the source of
cytoplasmic ADPr, which led to TRPM2 channel activation (8), we
hypothesize that OAADPr generated by SIRT3 is released from the
mitochondria during puromycin treatment. In the case of SIRT2, pro-
tein deacetylation in the cytoplasm would lead to direct intracellular
accumulation of OAADPr. However, we cannot dismiss the possibility
that OAADPr is converted to ADPr by an esterase activity found in the
cytoplasm (16), and that this newly generated ADPr activates the
TRPM2 channel. Because the enzymatic source of ADPr in the mito-
chondria and the mechanism of mitochondrial ADPr release are not
known, it is possible that Sir2-generatedOAADPr is the source of mito-
chondrial ADPr.
Here, we provide the first evidence thatOAADPr, the product of the
Sir2 reaction, canmodulate cellular responses by regulating the opening
of the TRPM2 Ca2-permeable channel. Although acute accumulation
of OAADPr in our cell-based system may cause susceptibility to cell
death, these data suggest that at lower levels of OAADPr, Sir2-like
enzymes could modulate diverse cellular events by mediating cellular
Ca2 entry. Nonselective cation channels, like TRPM2, may play a role
in insulin secretion by regulating pancreatic -cell plasma membrane
potential, Ca2 levels, and thus glucose signaling and homeostasis (34).
Interestingly, TRPM2 is expressed in  islets, and we have shown that
OAADPr activates TRPM2 in a rat insulinoma cell line. TRPM2 chan-
nels and their activation byOAADPr-producing Sir2 enzymesmay pro-
vide amechanism for depolarization or Ca2 entry in insulin producing
-cells, which could lead to the control of insulin secretion and overall
glucose homeostasis. Intriguingly, a recent study showed that overex-
pression of SIRT1 in -pancreatic islets of transgenic mice resulted in
improved glucose tolerance and enhanced glucose-stimulated insulin
secretion (55). OAADPr adds to the list of NAD-derived second mes-
sengers (including ADPr, cyclic-ADPr and NAAD(P)) that regulate
Ca2 signaling/release, and mediate cell survival (61).
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